These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The AMPA receptor as a therapeutic target: current perspectives and emerging possibilities. Mellor IR Future Med Chem; 2010 May; 2(5):877-91. PubMed ID: 21426207 [TBL] [Abstract][Full Text] [Related]
7. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Lees GJ Drugs; 2000 Jan; 59(1):33-78. PubMed ID: 10718099 [TBL] [Abstract][Full Text] [Related]
8. AMPA receptor ligands: synthetic and pharmacological studies of polyamines and polyamine toxins. Strømgaard K; Mellor I Med Res Rev; 2004 Sep; 24(5):589-620. PubMed ID: 15224382 [TBL] [Abstract][Full Text] [Related]
9. Positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. Grove SJ; Jamieson C; Maclean JK; Morrow JA; Rankovic Z J Med Chem; 2010 Oct; 53(20):7271-9. PubMed ID: 20839777 [No Abstract] [Full Text] [Related]
10. [Allosteric modulators of AMPA type glutamate receptors a novel gubclass of physiologically active substances]. Raevskiĭ KS; Eremin KO Biomed Khim; 2004; 50(6):523-38. PubMed ID: 15707268 [TBL] [Abstract][Full Text] [Related]
11. A role for AMPA receptors in mood disorders. Alt A; Nisenbaum ES; Bleakman D; Witkin JM Biochem Pharmacol; 2006 Apr; 71(9):1273-88. PubMed ID: 16442080 [TBL] [Abstract][Full Text] [Related]
12. Competitive AMPA receptor antagonists. Catarzi D; Colotta V; Varano F Med Res Rev; 2007 Mar; 27(2):239-78. PubMed ID: 16892196 [TBL] [Abstract][Full Text] [Related]
13. Methods for evaluation of positive allosteric modulators of glutamate AMPA receptors. Siuda ER; Quirk JC; Nisenbaum ES Methods Mol Biol; 2007; 403():37-57. PubMed ID: 18827986 [TBL] [Abstract][Full Text] [Related]
14. AMPA receptor potentiators for the treatment of CNS disorders. O'Neill MJ; Bleakman D; Zimmerman DM; Nisenbaum ES Curr Drug Targets CNS Neurol Disord; 2004 Jun; 3(3):181-94. PubMed ID: 15180479 [TBL] [Abstract][Full Text] [Related]
15. Structural aspects of AMPA receptor activation, desensitization and deactivation. Hansen KB; Yuan H; Traynelis SF Curr Opin Neurobiol; 2007 Jun; 17(3):281-8. PubMed ID: 17419047 [TBL] [Abstract][Full Text] [Related]
16. Structure and different conformational states of native AMPA receptor complexes. Nakagawa T; Cheng Y; Ramm E; Sheng M; Walz T Nature; 2005 Feb; 433(7025):545-9. PubMed ID: 15690046 [TBL] [Abstract][Full Text] [Related]
17. Three-dimensional structure of an AMPA receptor without associated stargazin/TARP proteins. Nakagawa T; Cheng Y; Sheng M; Walz T Biol Chem; 2006 Feb; 387(2):179-87. PubMed ID: 16497150 [TBL] [Abstract][Full Text] [Related]
18. Distinct structural features of cyclothiazide are responsible for effects on peak current amplitude and desensitization kinetics at iGluR2. Hald H; Ahring PK; Timmermann DB; Liljefors T; Gajhede M; Kastrup JS J Mol Biol; 2009 Sep; 391(5):906-17. PubMed ID: 19591837 [TBL] [Abstract][Full Text] [Related]
19. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Yang CR; Svensson KA Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436 [TBL] [Abstract][Full Text] [Related]
20. AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook. Chang PK; Verbich D; McKinney RA Eur J Neurosci; 2012 Jun; 35(12):1908-16. PubMed ID: 22708602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]